Avoid common mistakes on your manuscript.
Erratum to: Cancer Chemother Pharmacol DOI 10.1007/s00280-007-0473-0
Erlotinib was erroneuosly included in the list of chemotherapeutic agents in the second sentence of paragraph 4 in Discussion. The first two sentences of this paragraph should thus read:
Many chemotherapeutic agents have been used in over 12 separate phase II or III doublet combinations with gemcitabine, many of which went on to become negative trials in large phase III studies in pancreatic cancer. These included oxaliplatin [21], cisplatin [22], irinotecan [23] and capecitabine [10, 16].
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s00280-007-0473-0.
Rights and permissions
About this article
Cite this article
Fine, R.L., Fogelman, D.R., Schreibman, S.M. et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 61, 177 (2008). https://doi.org/10.1007/s00280-007-0569-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-007-0569-6